This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Exact Sciences (EXAS) Q4 Earnings and Revenues Rise Y/Y
by Zacks Equity Research
Exact Sciences' (EXAS) fourth-quarter 2019 results reflect strong segmental performances.
LabCorp (LH) Rides on Solid Diagnostics Despite PAMA Issues
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development delivers organic growth despite foreign currency headwind.
Here's Why You Should Add Hill-Rom to Your Portfolio Now
by Zacks Equity Research
Investor confidence is at a high, thanks to Hill-Rom (HRC) solid prospects.
STERIS (STE) Surpasses Q3 Earnings Estimates, Ups FY20 View
by Zacks Equity Research
STERIS' (STE) third-quarter fiscal 2020 results reflect strong segmental performances.
Buy These 5 Stocks With Attractive Sales Growth Right Now
by Swayta Shah
Sales growth is an important metric for any company, as it is a vital part of growth projections and instrumental in strategic decision making.
Here's Why You Should Add Zimmer (ZBH) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Zimmer's (ZBH) potential on its strong segmental and international results for the fiscal fourth quarter.
Hologic Expands Panther Portfolio With New Product Offerings
by Zacks Equity Research
Hologic's (HOLX) latest offerings are set to improve flexibility and efficiency of laboratories.
Omnicell (OMCL) Lags Q4 Earnings Estimates, Beats on Revenues
by Zacks Equity Research
Omnicell (OMCL) fourth-quarter 2019 results reflect strong segmental performances.
ResMed (RMD) Rides on New Product Portfolio, SaaS Growth
by Zacks Equity Research
Within SaaS, ResMed (RMD) consistently gains momentum from the Brightree service portfolio and derives synergies from the accretive MatrixCare buyout.
Here's Why You Should Add ResMed (RMD) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD), given its strong segmental and international fiscal second-quarter results.
Zacks.com featured highlights include: MSFT, RUTH, RMD, CDNS, CRL and MXIM
by Zacks Equity Research
Zacks.com featured highlights include: MSFT, RUTH, RMD, CDNS, CRL and MXIM
ResMed (RMD) Stock Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
ResMed (RMD) is optimistic about maintaining growth momentum on several recent developments.
Haemonetics (HAE) Q3 Earnings & Revenues Beat, Margins Expand
by Zacks Equity Research
Haemonetics (HAE) fiscal third-quarter 2020 results reflect strong performances in Plasma and Hospital segments.
Boston Scientific (BSX) Q4 Earnings Beat, Margins Decline
by Zacks Equity Research
Boston Scientific (BSX) is steadily investing in new technologies as well as the global markets, reflecting its uptick in sales across most geographies in Q4.
Here's Why You Should Retain IDEXX Laboratories Stock Now
by Zacks Equity Research
Investor confidence remains high in IDEXX (IDXX) stock, thanks to solid prospects.
6 GARP Stocks to Scoop Up for Maximum Returns
by Zacks Equity Research
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) exhibits robust growth in the second quarter of fiscal 2020, fueled by the strong performance of both its segment.
ResMed (RMD) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 19.80% and 1.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
COPD Devices Gain Regulatory Go-Ahead: 3 Stocks in Focus
by Sriparna Ghosal
Growth in the COPD devices market can be attributed to factors like steadily rising geriatric population, increasing incidence of smoking and chronic respiratory diseases.
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ResMed Launches AirFit F30i CPAP Mask, Widens Client Base
by Zacks Equity Research
ResMed (RMD) launches its first tube-up, full-face CPAP mask, thus completing its full-face mask portfolio.
NUVA vs. RMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
NUVA vs. RMD: Which Stock Is the Better Value Option?
Strong Pipeline Aids Tandem Diabetes Despite Stiff Rivalry
by Zacks Equity Research
Tandem Diabetes' (TNDM) products under development comprise AID systems, a next-generation hardware platform and connected (mobile) health offerings.
Product Launches Aid Intersect ENT (XENT) Despite Cost Woes
by Zacks Equity Research
Intersect ENT (XENT) recently closes its ENCORE study, a small 50-patient open label program designed to evaluate the safety of the repetitive use of SINUVA.
Bruker (BRKR) Rides High on Strong Nano Sales, New Buyouts
by Zacks Equity Research
Bruker (BRKR) is reaping solid synergy benefits from the acquisitions of Anasys, JPK and Alicona.